Livorsi Daniel J, Packiam Vignesh T, Shi Qianyi, Alberding Steven Y, Carter Knute D, Brown James A, Mason James B, Weiss Jeffrey P, Steinberg Ryan L
Iowa City Veterans' Administration Health Care System, Iowa City, IA, USA.
Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Infect Control Hosp Epidemiol. 2024 Nov 7;46(1):1-7. doi: 10.1017/ice.2024.172.
Post-procedural antimicrobial prophylaxis is not recommended by professional guidelines but is commonly prescribed. We sought to reduce use of post-procedural antimicrobials after common endoscopic urologic procedures.
A before-after, quasi-experimental trial with a baseline (July 2020-June 2022), an implementation (July 2022), and an intervention period (August 2022-July 2023).
Three participating medical centers.
We assessed the effect of a bundled intervention on excess post-procedural antimicrobial use (, antimicrobial use on post-procedural day 1) after three types of endoscopic urologic procedures: ureteroscopy and transurethral resection of bladder tumor or prostate. The intervention consisted of education, local champion(s), and audit-and-feedback of data on the frequency of post-procedural antimicrobial-prescribing.
1,272 procedures were performed across all 3 sites at baseline compared to 525 during the intervention period; 644 (50.6%) patients received excess post-procedural antimicrobials during the baseline period compared to 216 (41.1%) during the intervention period. There was no change in the use of post-procedural antimicrobials at sites 1 and 2 between the baseline and intervention periods. At site 3, the odds of prescribing a post-procedural antimicrobial significantly decreased during the intervention period relative to the baseline time trend (0.09; 95% CI 0.02-0.45). There was no significant increase in post-procedural unplanned visits at any of the sites.
Implementation of a bundled intervention was associated with reduced post-procedural antimicrobial use at one of three sites, with no increase in complications. These findings demonstrate both the safety and challenge of guideline implementation for optimal perioperative antimicrobial prophylaxis.This trial was registered on clinicaltrials.gov, NCT04196777.
专业指南不推荐术后使用抗菌药物进行预防,但这种做法却很常见。我们试图减少常见泌尿外科内镜手术后的术后抗菌药物使用。
一项前后对照的准实验性试验,包括基线期(2020年7月至2022年6月)、实施期(2022年7月)和干预期(2022年8月至2023年7月)。
三个参与研究的医疗中心。
我们评估了综合干预措施对三种泌尿外科内镜手术后过度使用术后抗菌药物(即术后第1天使用抗菌药物)的影响,这三种手术分别是输尿管镜检查以及膀胱肿瘤或前列腺经尿道切除术。干预措施包括教育、设立当地负责人以及对术后抗菌药物处方频率数据进行审核与反馈。
在基线期,所有三个研究地点共进行了1272例手术,而在干预期为525例;在基线期,644例(50.6%)患者术后过度使用了抗菌药物,而在干预期这一数字为216例(41.1%)。在研究地点1和2,基线期与干预期之间术后抗菌药物的使用没有变化。在研究地点3,与基线期时间趋势相比,干预期开具术后抗菌药物的几率显著降低(0.09;95%置信区间0.02 - 0.45)。在任何一个研究地点,术后非计划就诊次数均未显著增加。
综合干预措施的实施与三个研究地点之一术后抗菌药物使用的减少相关,且并发症未增加。这些发现证明了实施指南以实现最佳围手术期抗菌药物预防的安全性和挑战性。本试验已在clinicaltrials.gov上注册,注册号为NCT04196777。